Comparison

COT (MAP3K8/MEKK8) Antibody (C-term) Blocking peptide

Item no. ABC-BP7913a
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Specific against other
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Similar products MAP3K8, COT, ESTF, Mitogen-activated protein kinase kinase kinase 8, Cancer Osaka thyroid oncogene, Proto-oncogene c-Cot, Serine/threonine-protein kinase cot, Tumor progression locus 2, TPL-2
Available
Primary Accession
P41279
Bio Background
Mitogen-activated protein kinase (MAPK) signaling cascades include MAPK or extracellular signal-regulated kinase (ERK), MAPK kinase (MKK or MEK), and MAPK kinase kinase (MAPKKK or MEKK). MAPKK kinase/MEKK phosphorylates and activates its downstream protein kinase, MAPK kinase/MEK, which in turn activates MAPK. The kinases of these signaling cascades are highly conserved, and homologs exist in yeast, Drosophila, and mammalian cells. MEKK8 is able to activate NF-kappa-B 1 by stimulating proteasome-mediated proteolysis of NF-kappa-B 1/p105. The protein appears to play an important role in the cell cycle. This cytoplasmic protein is expressed in several normal tissues and human tumor-derived cell lines. The 58 kDa form is activated specifically during the S and G2/M phases of the cell cycle. The longer form undergoes phosphorylation on Ser residues mainly, and the shorter form on both Ser and Thr residues.
Bio References
Sanchez-Gongora, E., et al., J. Biol. Chem. 275(40):31379-31386 (2000).Aoki, M., et al., J. Biol. Chem. 268(30):22723-22732 (1993).Chan, A.M., et al., Oncogene 8(5):1329-1333 (1993).Miyoshi, J., et al., Mol. Cell. Biol. 11(8):4088-4096 (1991).Aoki, M., et al., Oncogene 6(9):1515-1519 (1991).
Gene ID
1326
Gene Name
MAP3K8
Subtitle
Synthetic peptide
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP7913a was selected from the C-term region of human MEKK8 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close